Inovio Pharmaceuticals, Inc. Inovio Pharmaceuticals, Inc.

Inovio Pharmaceuticals, Inc.

INO

Hisse Senetlerindeki Sıralama #23526
Inovio Pharmaceuticals, Inc. is a biotechnology firm dedicated to the research,... Inovio Pharmaceuticals, Inc. is a biotechnology firm dedicated to the research, development, and market introduction of DNA-based treatments. Its core mission is to prevent and cure illnesses associated with human papillomavirus (HPV), various types of cancer, and infectious diseases. The company's advanced DNA medicine platform utilizes meticulously engineered SynCon sequences to precisely identify and optimize the genetic blueprint of a target antigen. This innovative approach is supported by its CELLECTRA smart device technology, which efficiently delivers the DNA plasmids. Inovio is actively engaged in and planning clinical trials for its DNA medicines across a wide array of conditions. These include HPV-related precancerous lesions, such as cervical, vulvar, and anal dysplasia; HPV-driven cancers affecting areas like the head and neck, cervix, anus, penis, vulva, and vagina; and other HPV-associated disorders like recurrent respiratory papillomatosis. Beyond HPV, its pipeline addresses glioblastoma multiforme, prostate cancer, and a range of infectious diseases, including HIV, Ebola, Middle East Respiratory Syndrome (MERS), and Lassa fever. The company benefits from a vast network of collaborators and partners, encompassing prominent academic institutions, government agencies, non-profit foundations, and pharmaceutical corporations. Key examples include AstraZeneca, The Bill & Melinda Gates Foundation, the Coalition for Epidemic Preparedness Innovations (CEPI), the Defense Advanced Research Projects Agency (DARPA), the National Institutes of Health, Regeneron Pharmaceuticals, and the University of Pennsylvania. Significant partnerships also involve an agreement with Richter-Helm BioLogics GmbH & Co. KG to further develop the investigational COVID-19 DNA vaccine INO-4800, alongside a strategic alliance with the International Vaccine Institute and Seoul National University Hospital. Established in 1979, Inovio Pharmaceuticals is headquartered in Plymouth Meeting, Pennsylvania.
Hisse Fiyatı
$0.9994
Son senkronizasyon: 2026-10-16
Piyasa Değeri
$69.05M
Değişim (1 gün)
-3.90%
Değişim (1 yıl)
-87.57%
Ülke
US
Ticaret Inovio Pharmaceuticals, Inc. (INO)

Kategori

Healthcare
Inovio Pharmaceuticals, Inc. (INO) için Faaliyet Marjı
2026 itibarıyla Faaliyet Marjı TTM: 0.00%
Inovio Pharmaceuticals, Inc. şirketinin en son finansal raporlarına ve hisse fiyatına göre, mevcut faaliyet marjı (TTM) 0.00%'dir. 2026 yılı sonunda şirketin faaliyet marjı 0.00% idi.
Inovio Pharmaceuticals, Inc. için 2026 ile 2026 arasındaki Faaliyet Marjı geçmişi
Her yıl sonunda Faaliyet Marjı
Yıl Faaliyet Marjı Değiştir
Sağlanan tarihler için yeterli veri yok.
Benzer şirketler veya rakipler için Faaliyet Marjı
Şirket Faaliyet Marjı Faaliyet Marjı Farkı Ülke
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.59% -
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
-149.01% -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
25.57% -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -
NL
Bir şirketin Faaliyet Marjı'ı nedir?
Faaliyet Marjı, bir şirketin kârlılığını değerlendirmek için temel bir göstergedir. Daha yüksek Faaliyet Marjı değerleri genellikle daha iyidir çünkü bir şirketin ürün veya hizmetlerini üretim maliyetlerinden çok daha yüksek bir fiyata satabildiğini gösterir. Faaliyet Marjı, şirketin kârının gelirine bölünmesiyle hesaplanır.